165 related articles for article (PubMed ID: 10200461)
1. The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis.
Dickinson JL; Norris BJ; Jensen PH; Antalis TM
Cell Death Differ; 1998 Feb; 5(2):163-71. PubMed ID: 10200461
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
[TBL] [Abstract][Full Text] [Related]
3. Analysis of serpin inhibitory function by mutagenesis of ovalbumin and generation of chimeric ovalbumin/PAI-2 fusion proteins.
McCarthy BJ; Worrall DM
J Mol Biol; 1997 Apr; 267(3):561-9. PubMed ID: 9126838
[TBL] [Abstract][Full Text] [Related]
4. Identification of interaction between PAI-2 and IRF-3.
Zhang YQ; Li P; Hou M; Wang X; Fan J; Tan L; Zhu YS
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jul; 35(7):661-5. PubMed ID: 12883638
[TBL] [Abstract][Full Text] [Related]
5. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
6. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.
Medcalf RL; Stasinopoulos SJ
FEBS J; 2005 Oct; 272(19):4858-67. PubMed ID: 16176260
[TBL] [Abstract][Full Text] [Related]
7. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells.
Chen YQ; Sloan-Lancaster J; Berg DT; Richardson MA; Grinnell B; Tseng-Crank J
Thromb Haemost; 2001 Dec; 86(6):1563-72. PubMed ID: 11776328
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.
Dickinson JL; Bates EJ; Ferrante A; Antalis TM
J Biol Chem; 1995 Nov; 270(46):27894-904. PubMed ID: 7499264
[TBL] [Abstract][Full Text] [Related]
9. Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis.
Fish RJ; Kruithof EK
Exp Cell Res; 2006 Feb; 312(3):350-61. PubMed ID: 16330024
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
Hamaguchi E; Takamura T; Shimizu A; Nagai Y
J Pharmacol Exp Ther; 2003 Dec; 307(3):987-94. PubMed ID: 14534369
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the level and glycosylation state of plasminogen activator inhibitor type 2 during human keratinocyte differentiation.
Wang Y; Jensen PJ
Differentiation; 1998 Jun; 63(2):93-9. PubMed ID: 9674118
[TBL] [Abstract][Full Text] [Related]
12. The enigma PAI-2. Gene expression, evolutionary and functional aspects.
Bachmann F
Thromb Haemost; 1995 Jul; 74(1):172-9. PubMed ID: 8578452
[TBL] [Abstract][Full Text] [Related]
13. Maspin sensitizes breast carcinoma cells to induced apoptosis.
Jiang N; Meng Y; Zhang S; Mensah-Osman E; Sheng S
Oncogene; 2002 Jun; 21(26):4089-98. PubMed ID: 12037665
[TBL] [Abstract][Full Text] [Related]
14. Focused PCR screen reveals p53 dependence of nitric oxide-induced apoptosis and up-regulation of maspin and plasminogen activator inhibitor-1 in tumor cells.
Lim S; Hung AC; Porter AG
Mol Cancer Res; 2009 Jan; 7(1):55-66. PubMed ID: 19147537
[TBL] [Abstract][Full Text] [Related]
15. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.
Aertgeerts K; De Ranter CJ; Booth NA; Declerck PJ
J Struct Biol; 1997 Apr; 118(3):236-42. PubMed ID: 9169233
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
[TBL] [Abstract][Full Text] [Related]
17. Thrombin inhibits apoptosis of monocytes and plasminogen activator inhibitor 2 (PAI-2) is not responsible for this inhibition.
Ritchie H; Fragoyannis A
Exp Cell Res; 2000 Oct; 260(1):20-9. PubMed ID: 11010807
[TBL] [Abstract][Full Text] [Related]
18. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of serpin squamous cell carcinoma antigen 2 in human tumor tissues and cell lines: evidence of protection from tumor necrosis factor-mediated apoptosis.
Takeda A; Kajiya A; Iwasawa A; Nakamura Y; Hibino T
Biol Chem; 2002; 383(7-8):1231-6. PubMed ID: 12437110
[TBL] [Abstract][Full Text] [Related]
20. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
